These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

213 related items for PubMed ID: 4096611

  • 1. Pharmacokinetics of biliary excretion of physostigmine in rat.
    Boyer AW, Somani SM.
    Arch Int Pharmacodyn Ther; 1985 Dec; 278(2):180-92. PubMed ID: 4096611
    [Abstract] [Full Text] [Related]

  • 2. Hepatic and muscle clearance of physostigmine in the rat.
    Unni LK, Somani SM.
    Drug Metab Dispos; 1986 Dec; 14(2):183-9. PubMed ID: 2870892
    [Abstract] [Full Text] [Related]

  • 3. Pharmacokinetics and pharmacodynamics of physostigmine in the rat after intravenous administration.
    Somani SM, Khalique A.
    Drug Metab Dispos; 1987 Dec; 15(5):627-33. PubMed ID: 2891478
    [Abstract] [Full Text] [Related]

  • 4. Distribution and pharmacokinetics of physostigmine in rat after intramuscular administration.
    Somani SM, Khalique A.
    Fundam Appl Toxicol; 1986 Feb; 6(2):327-34. PubMed ID: 3699321
    [Abstract] [Full Text] [Related]

  • 5. Urinary pharmacokinetics of physostigmine in the rat.
    Somani SM, Boyer A.
    Eur J Drug Metab Pharmacokinet; 1985 Feb; 10(4):343-7. PubMed ID: 3830722
    [Abstract] [Full Text] [Related]

  • 6. Biliary excretion of colchicine.
    Hunter AL, Klaassen CD.
    J Pharmacol Exp Ther; 1975 Mar; 192(3):605-17. PubMed ID: 1120958
    [Abstract] [Full Text] [Related]

  • 7. alpha-Bromoisovalerylurea as model substrate for studies on pharmacokinetics of glutathione conjugation in the rat. II. Pharmacokinetics and stereoselectivity of metabolism and excretion in vivo and in the perfused liver.
    te Koppele JM, Dogterom P, Vermeulen NP, Meijer DK, van der Gen A, Mulder GJ.
    J Pharmacol Exp Ther; 1986 Dec; 239(3):905-14. PubMed ID: 3795049
    [Abstract] [Full Text] [Related]

  • 8. Pharmacokinetics of nimodipine. I. Communication: absorption, concentration in plasma and excretion after single administration of [14C]nimodipine in rat, dog and monkey.
    Maruhn D, Siefert HM, Weber H, Rämsch K, Suwelack D.
    Arzneimittelforschung; 1985 Dec; 35(12):1781-6. PubMed ID: 4096729
    [Abstract] [Full Text] [Related]

  • 9. Biliary excretion of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) and metabolites by Fischer 344 rats.
    Musser SM, Egorin MJ, Zuhowski EG, Hamburger DR, Parise RA, Covey JM, White KD, Eiseman JL.
    Cancer Chemother Pharmacol; 2003 Aug; 52(2):139-46. PubMed ID: 12761648
    [Abstract] [Full Text] [Related]

  • 10. Disposition and metabolism of the new hypocholesterolemic compound S-8921 in rats and dogs.
    Yamaguchi T, Nakajima Y, Mizobuchi M, Inazawa K, Kanazu T, Kadono K, Ohkawa T, Iwatani K.
    Arzneimittelforschung; 1998 Oct; 48(10):995-1006. PubMed ID: 9825117
    [Abstract] [Full Text] [Related]

  • 11. Distribution and excretion of (3H)vincristine in the rat and the dog.
    Castle MC, Margileth DA, Oliverio VT.
    Cancer Res; 1976 Oct; 36(10):3684-9. PubMed ID: 953993
    [Abstract] [Full Text] [Related]

  • 12. Effects of biliary excretion on the disposition of felodipine and metabolites in the rat.
    Sutfin TA, Gabrielsson M, Regårdh CG.
    Xenobiotica; 1987 Oct; 17(10):1203-14. PubMed ID: 3424867
    [Abstract] [Full Text] [Related]

  • 13. The disposition and pharmacokinetics of ketoconazole in the rat.
    Remmel RP, Amoh K, Abdel-Monem MM.
    Drug Metab Dispos; 1987 Oct; 15(6):735-9. PubMed ID: 2893696
    [Abstract] [Full Text] [Related]

  • 14. Non-linear pharmacokinetics of sparteine in the rat.
    Van der Graaff M, Vermeulen NP, Koperdraat MC, Breimer DD.
    Arch Int Pharmacodyn Ther; 1986 Aug; 282(2):181-95. PubMed ID: 3767526
    [Abstract] [Full Text] [Related]

  • 15. Disposition and metabolism of indeloxazine hydrochloride, a cerebral activator, in rats.
    Kamimura H, Enjoji Y, Sasaki H, Kawai R, Kaniwa H, Niigata K, Kageyama S.
    Xenobiotica; 1987 Jun; 17(6):645-58. PubMed ID: 3630201
    [Abstract] [Full Text] [Related]

  • 16. The metabolic disposition of (S)-2-(3-tert-butylamino-2-hydroxypropoxy)-3-cyanopyridine in rats, dogs, and humans.
    Vickers S, Duncan CA, Arison BH, Davies RO, Ferguson R, Zacchei AG.
    Drug Metab Dispos; 1980 Jun; 8(3):163-7. PubMed ID: 6104580
    [Abstract] [Full Text] [Related]

  • 17. The disposition of primaquine in the isolated perfused rat liver. Effect of dose size.
    Ward SA, Mihaly GW, Nicholl DD, Edwards G, Breckenridge AM.
    Drug Metab Dispos; 1985 Jun; 13(4):425-9. PubMed ID: 2863105
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Pharmacokinetics and pharmacodynamics of physostigmine in the rat after oral administration.
    Somani SM.
    Biopharm Drug Dispos; 1989 Jun; 10(2):187-203. PubMed ID: 2706318
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.